SPO Medical Launches its Technology in Sports Market

Company Secures Project Funding and Potential for Future Royalty Payments

PR Newswire

NEW YORK, February 9

NEW YORK, February 9 /PRNewswire-FirstCall/ — SPO Medical Inc. (SPOM), a
leading developer of biosensor and microprocessor technologies for use in
portable monitoring devices, today announced it has signed a Memorandum of
Understanding (MOU) with SporTracker Ltd, a private Israeli company that
specializes in the integration of heart-rate monitoring with consumer audio
and leisure devices. The MOU contemplates bundling SPO Medical monitoring
technology in new SporTracker recreational products. The terms include
advance payments for development work to be performed by SPO on behalf of
SporTracker and subsequent royalty payments once the developed products are
commercially available. This arrangement follows the recent restructuring of
SPO Medical Inc. enabling SPO to focus on various new commercial
opportunities relating to the implementation of reflectance pulse oximetry
for non-medical market applications.

Michael Braunold, President and Chief Executive Officer of SPO Medical
commented: "The commercial arrangement with SporTracker demonstrates the
portability of our proven technology into markets and applications which can
benefit from our experience to date. The sports and wellness sector is a
mass-market opportunity for our technology enabling monitoring of certain
vital sign information in conjunction with leisure related configurations."

Dani Ne'eman, President of SporTracker Ltd commented: "We selected SPO as
our technology provider due to their commercial track-record and proven
experience in low-power measurements of heart rate and the ease to integrate
this technology in to popular consumer audio and leisure devices. We envisage
initial commercial sales of our products incorporating the SPO technology to
commence during 2011 followed by a wider worldwide product launch via our
strategic marketing partners. The SPO technology enables us to deliver a
potentially superior product offering which could have a major impact on the
general sports market that incorporates audio and leisure related devices."

SPO Medical Inc. recently announced that it plans to embark on business
development activities that focus on various commercial applications relating
to the implementation of reflectance pulse oximetry for non-medical markets.
Braunold continued; "Commercially, we believe that our unique technology can
attract interest from various non-medical entities who are seeking commercial
solutions based on our deliverable for mass-market consumer markets."

About SPO Medical:

SPO Medical (SPOM) a leading developer of biosensor and microprocessor
technologies for use in portable monitoring devices to capture life-saving
and life-enhancing information within four key markets: medical care; home
and remote-care; sports and wellness; and safety and security. Its patented
technology uses information gathered from the reflectance of light on the
human blood stream, in a non-invasive manner, to monitor key vital signs. The
Company licenses its technologies to appropriate client corporations for
commercialization and distribution. For more information, visit
http://www.spomedical.com and http://www.spobaby.com.

Forward Looking Statements:

This press release contains forward-looking statements that involve
substantial uncertainties and risks. These forward-looking statements are
based upon our current expectations, estimates and projections about our
business and our industry, and that reflect our beliefs and assumptions based
upon information available to us at the date of this release. We caution
readers that forward-looking statements are predictions based on our current
expectations about future events. These forward-looking statements are not
guarantees of future performance and are subject to risks, uncertainties and
assumptions that are difficult to predict. Our actual results, performance or
achievements could differ materially from those expressed or implied by the
forward-looking statements as a result of a number of factors, including but
not limited to, patent protection for our products and technologies, market
acceptance of our products and new product applications, product performance,
size of prospective markets, revenues assessments, changes in economic
conditions generally and the medical devices market specifically, changes in
technology, legislative or regulatory changes that affect us, the sufficiency
and availability of working capital, the introduction of competing products,
changes in our operating strategy or development plans and the risks and
uncertainties discussed under the heading "Risk Factors" in Item 1 of our
Annual Report on Form 10-K for the fiscal year ended December 31, 2008. We
undertake no obligation to revise or update any forward-looking statement for
any reason.

    SPO Medical Contact:
    Michael Braunold, Chief Executive Officer.
    investors@spomedical.com
    +1-866-991-7766

SOURCE SPO Medical Inc.

Contact

SPO Medical Contact: Michael Braunold, Chief Executive Officer, investors@spomedical.com, +1-866-991-7766